Andere Sprachen Dicot Pharma AB

Aktien

Schlusskurs NORDIC GROWTH MARKET Andere Börsenplätze 00:00:00 28.06.2024			% 5 Tage	% 1. Jan.
0.379 ^SEK	-18.32%		-6.88%	+19.18%

06.06.	Dicot Pharma AB entwickelt LIB-01 zu einem Medikament mit neuer Potenz und verbesserten Eigenschaften im Vergleich zu derzeit erhältlichen Medikamenten	CI
06.05.	Dicot AB (publ) meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI

Dicot Pharma: Experts from Dicot Pharma's clinical study behind submitted abstract	19.06.
Experts from Dicot Pharma's clinical study behind submitted abstract	18.06.
LIB-01 appears to affect metabolic diseases and Dicot Pharma files new patent application	06.06.
Dicot Pharma AB Develops LIB-01 into A New Potency Drug with Improved Properties Compared to Currently Available Drugs	06.06.
Today Dicot AB becomes Dicot Pharma AB	30.05.
Dicot presents interim report Q1 2024	06.05.
Dicot Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	06.05.
Dicot AB has Changed its Name to Dicot Pharma AB	06.05.
Good safety and improved erectile function reported from Dicot's phase 1 study	23.04.
Dicot AB Announces Positive Safety and Improved Efficacy Results from Phase 1 Study	23.04.
Dicot in preparation for clinical phase 2a trial	12.04.
Reporting from Dicot's phase 1 study end of April	05.04.
BioStock: Dicot's phase I study fully recruited	14.03.
Recruitment completed in Dicot's phase 1 trial	11.03.
Dicot AB Announces Recruitment Completed in Dicot's Phase 1 Trial	11.03.
Dicot's CEO tells BioStock: "Several prominent people want to be part of the journey"	29.02.
Dicot AB Year-End Report 2023	26.02.
Dicot AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	26.02.
BioStock: Good safety profile for Dicot's LIB-01	26.01.
Positive results from the first part of Dicot's phase 1 study	23.01.

Keine Ergebnisse zu dieser Suche